The Technical Analyst
LivaNova PLC [LIVN]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
LivaNova PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.67% $55.94
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 018.31 mill |
| EPS: | 0.320 |
| P/E: | 174.81 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 53.96 mill |
| Avg Daily Volume: | 0.659 mill |
| RATING 2024-04-24 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 174.81 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.79x |
| Company: PE 174.81 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-8.11 (-114.51%) $-64.05 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 54.21 - 57.67 ( +/- 3.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-30 | Bolton Stephanie | Buy | 7 744 | Ordinary Shares |
| 2024-03-30 | Bolton Stephanie | Buy | 10 746 | Stock Appreciation Rights |
| 2024-03-30 | Bolton Stephanie | Sell | 3 643 | Ordinary Shares |
| 2024-03-30 | Bolton Stephanie | Buy | 4 915 | Restricted Stock Units |
| 2024-03-30 | Bolton Stephanie | Buy | 4 915 | Performance Stock Units |
| INSIDER POWER |
|---|
| 50.89 |
| Last 100 transactions |
| Buy: 371 593 | Sell: 126 373 |
Forecast:
16:00 - $55.93
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $55.93
Forecast 2: 16:00 - $55.93
Forecast 3: 16:00 - $55.93
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $55.94 (1.67% ) |
| Volume | 0.546 mill |
| Avg. Vol. | 0.659 mill |
| % of Avg. Vol | 82.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LIVN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $50.42 | N/A | Active |
|---|
LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Last 10 Buy Signals
Latest Press Releases
2024-03-21 09:00:00 - Press Release
Livanova To Announce First-quarter 2024 Results
London--(business wire)-- #advancedcirculatorysupport--livanova will host a conference call to discuss its first-quarter 2024 results on wed, may 1, 2024 at 1 p.m. london time (8 a.m. et).
2024-03-20 09:00:00 - Press Release
Livanova Announces A Positive Predictive Outcome Of Trial Success In Its Osprey Clinical Study For Moderate To Severe Obstructive Sleep Apnea
London--(business wire)-- #cardiacsurgery--livanova plc announced its osprey clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
2024-03-05 21:55:00 - Press Release
Livanova Announces Pricing Of Private Offering Of $300 Million Of 2.50% Convertible Senior Notes Due 2029
London--(business wire)-- #cardiacsurgery--livanova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
2024-03-04 16:44:00 - Press Release
Livanova Announces Proposed Private Offering Of $300 Million Of Convertible Senior Notes
London--(business wire)-- #cardiacsurgery--livanova plc announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
2024-03-04 09:00:00 - Press Release
Livanova To Present At The Barclays Global Healthcare Conference
London--(business wire)-- #advancedcirculatorysupport--livanova announced vladimir makatsaria, ceo, will present in a fireside chat at the barclays conference in miami, florida at 10:45 am et on march 12.
Latest News
2024-03-21 05:51:06 - Zacks Investment Research
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-02-21 08:11:05 - Zacks Investment Research
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.81 per share a year ago.
2023-12-26 18:00:00 - Seeking Alpha
LivaNova: Reaching End Of RECOVER And ANTHEM
LivaNova is approaching the end of the ANTHEM and RECOVER which could dramatically change the company profile. In cardiopulmonary results are great with a new product launch of Essenz taking market share at premium prices. Run-rate PEs aren't that high, and a languishing price means a setup here that could be attractive once the trials start to demonstrate concrete promise in 2024.
2023-11-01 13:26:04 - Seeking Alpha
LivaNova PLC (LIVN) Q3 2023 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development & IT Bill Cozy - Chairman and Interim Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants Rick Wise - Stiefel Mike Polark - Wolfe Research Adam Maeder - Piper Sandler Matt Taylor - Jefferies Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Matt Miksic - Barclays David Rescott - Baird Operator Good day, ladies and gentlemen and welcome to the LivaNova PLC Third Quarter of 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
2023-08-16 19:07:03 - InvestorPlace
The 7 Most Undervalued Healthcare Stocks to Buy Now: August 2023
Investors always hope to buy low and sell high. In order to do so, it's necessary to identify stocks that are undervalued.
2023-07-26 08:40:15 - Zacks Investment Research
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.53 per share a year ago.
2023-05-10 12:35:34 - GuruFocus
Primecap Management Pumps Up LivaNova Position
Media-shy investment firm PRIMECAP Management (Trades, Portfolio) revealed earlier this week it upped its stake in LivaNova PLC ( LIVN , Financial), which had an impact of 0.04% on the equity portfolio.
2023-05-07 11:48:09 - Seeking Alpha
LivaNova PLC (LIVN) Q1 2023 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development William Kozy - Chairman & Interim Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Michael Polark - Wolfe Research Matthew Taylor - Jefferies Adam Maeder - Piper Sandler Mike Matson - Needham & Company Operator Good day ladies and gentlemen and welcome to the LivaNova PLC First Quarter of 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
2023-05-03 09:07:43 - Zacks Investment Research
LivaNova (LIVN) Beats Q1 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.48 per share a year ago.
2023-04-18 09:56:41 - Zacks Investment Research
Strength Seen in LivaNova (LIVN): Can Its 12.7% Jump Turn into More Strength?
LivaNova (LIVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.